skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

Original Research

(2581) Views  (589) Full article downloads

Authors: Sunanda Kane, William Holderman, Peter Jacques, Todd Miodek

Published Date September 2008 Volume 2008:2 Pages 253 - 258
DOI: http://dx.doi.org/10.2147/PPA.S3698

Sunanda Kane1, William Holderman2, Peter Jacques2, Todd Miodek3

1Mayo Clinic College of Medicine, Rochester, MN, USA; 2Digestive Health Specialists, Tacoma, WA, USA; 3University of Chicago, Chicago, IL, USA

Background and Aims: Multiple studies have demonstrated the efficacy of aminosalicylates in maintaining remission in ulcerative colitis (UC). A newer formulation of mesalamine can be administered once daily. We aimed to examine the efficacy and tolerability of pH-dependent mesalamine for long-term maintenance, and compare the rates of medication consumption between groups over a prolonged period.

Methods: Subjects whose UC had been quiescent for at least 4 months, and who had been receiving mesalamine for maintenance only, were randomized to once daily or conventional dosing for 12 months. Disease activity and medication consumption was assessed every 3 months. The primary endpoint was the percentage of those with quiescent disease at 12 months.

Results: We enrolled 20 patients, 12 to once daily and 8 to conventional dosing. Six of the 12 patients (50%) in the once daily group compared with 5 of the 8 patients (62.5%) in the conventional group experienced a flare (p = 0.31). Only 5 of the 12 (42%) patients in the once daily group were adherent compared with 3 of 8 patients (37.5%) in the conventional dosing group (p = NS). Median amount consumed in the once daily group was 63% (range 0%–100%) and in the conventional group 55% (range 0%–100%), (p > 0.5). None of the adherent subjects in the once daily group experienced a flare, while 6 out of 7 (86%) who were non-adherent experienced a flare (p < 0.01). In the conventional dosing group, 1 in 3 adherent patients (33%) experienced a fl are compared with 4 out of 5 (80%) in the non-adherent group (p < 0.01).

Conclusion: Adherence, rather than medication regimen, appeared to be important in disease outcome at 12 months.

Keywords: ulcerative colitis, mesalamine, aminosalicylates, remission






 

Other articles by Dr Sunanda Kane



Readers of this article also read:

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
Periosteoplasty for covering gingival recessions: Clinical results
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years
Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
Impact of an educational program on nursing students’ caring and self-perception in intensive clinical training in Jordan